Abstract
What is the origin of the complex vascular changes that exist in the CNS lesions of Multiple Sclerosis (MS)? From the beginning of the study of the pathological changes in MS in the 19th century, lesions were seen to be associated with veins. On a microscopic level, there have been numerous pathological changes to these vessels including altered structure and permeability, fibrinolysis, iron-related alterations and collagen deposition. Vascular changes in inflammatory conditions outside the CNS are well documented and we hypothesize that angiogenesis (the generation of new blood vessels from existing) is an integral process of lesion development and spread in MS. We demonstrated similar vascular abnormalities in MS and in the animal model, EAE. We measured the increase in angiogenesis-related genes in EAE and review herein the effectiveness of chemical inhibitors of angiogenesis (SU5416, thalidomide and several derivatives). We postulate that interference with angiogenesis provides a suitable non-immunological target for investigation in MS.
Keywords: thalidomide, Multiple sclerosis, neuroinflammation, EAE, angiogenesis, SU5416, CNS, blood-brain barrier (BBB)
Central Nervous System Agents in Medicinal Chemistry
Title:Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Volume: 12 Issue: 1
Author(s): Stephen J. Karlik, Wendi A. Roscoe, Cindy Patinote, Christiane Contino-Pepin
Affiliation:
Keywords: thalidomide, Multiple sclerosis, neuroinflammation, EAE, angiogenesis, SU5416, CNS, blood-brain barrier (BBB)
Abstract: What is the origin of the complex vascular changes that exist in the CNS lesions of Multiple Sclerosis (MS)? From the beginning of the study of the pathological changes in MS in the 19th century, lesions were seen to be associated with veins. On a microscopic level, there have been numerous pathological changes to these vessels including altered structure and permeability, fibrinolysis, iron-related alterations and collagen deposition. Vascular changes in inflammatory conditions outside the CNS are well documented and we hypothesize that angiogenesis (the generation of new blood vessels from existing) is an integral process of lesion development and spread in MS. We demonstrated similar vascular abnormalities in MS and in the animal model, EAE. We measured the increase in angiogenesis-related genes in EAE and review herein the effectiveness of chemical inhibitors of angiogenesis (SU5416, thalidomide and several derivatives). We postulate that interference with angiogenesis provides a suitable non-immunological target for investigation in MS.
Export Options
About this article
Cite this article as:
Stephen J. Karlik, Wendi A. Roscoe, Cindy Patinote, Christiane Contino-Pepin , Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/187152412800229125
DOI https://dx.doi.org/10.2174/187152412800229125 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets The p35 Family of Apoptosis Inhibitors
Current Genomics Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine Migration and Function of Th17 Cells
Inflammation & Allergy - Drug Targets (Discontinued) Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Chemokines and Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued)